SOD1 and amyotrophic lateral sclerosis: ASOs targeting SOD1 (ASOs-SOD1) are designed to reduce SOD1 expression, which holds promise for slowing the progression of ALS and prolonging patient survival during clinical treatment (Miller et al., 2020).